From Blood Sugar Control and Weight Loss to Cardiovascular Protection! Mounjaro Achieves "Cardiometabolic Leap," Eli Lilly (LLY.US) Opens Second Growth Curve for GLP-1

智通财经2026/08/28 12:36

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

```htmlAccording to Jinse Finance APP, Eli Lilly (LLY.US), a leader in the American healthcare industry, is comprehensively upgrading its blockbuster weight-loss drug Mounjaro—known as the “miracle weight-loss drug” and also effective in lowering blood sugar—from a product focused solely on weight loss and glucose reduction to an integrated treatment platform covering cardiovascular and metabolic complications. The US Food and Drug Administration has now approved Mounjaro for reducing the risk of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke in adults with type 2 diabetes and heart disease, further strengthening its competitive advantage over its largest rival, Novo Nordisk’s weight-loss and diabetes drug Ozempic.```

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

On Tuesday, following Federal Reserve Governor Waller’s call to consider a 50 basis point rate hike at the December meeting, this year’s FOMC rotating voting member Lorie Logan reiterated a hawkish stance, stating, "Given the current economic outlook, I believe at least two more rate hikes of 25 basis points each are needed. The pace of rate hikes this winter may be faster than what we have seen so far this autumn." On Tuesday, the two-year US Treasury yield jumped 19 basis points in a single day, reaching 4.74%.

华尔街见闻•2026/11/10 19:52